20n
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
20n was a San Francisco computational synthetic biology company founded in 2014 by computer scientist Saurabh Srivastava and UC Berkeley professor J. Christopher Anderson. Its software platform, 20n/act, predicted DNA insertions into microbes to engineer organisms that produce target chemicals through fermentation, including the first known biosynthetic route to acetaminophen, and licensed those designs to industrial customers.
02 / 20n FAILURE REASONS
Failure reasons
The failure was commercial, not scientific. 20n built a design-only software layer and outsourced DNA synthesis and validation to contract research organizations, while vertically integrated competitors like Ginkgo Bioworks and Zymergen owned the full design-build-test loop with their own wet labs. Industrial customers buying fermentation processes face multi-year validation cycles, a pace incompatible with a lean software-speed startup; the company quietly wound down between 2017 and 2018.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Saurabh Srivastava and J. Christopher Anderson found 20n in San Francisco based on their UC Berkeley research in program synthesis applied to synthetic biology.
- Product launch
20n enters Y Combinator Winter 2015, presents the 20n/act platform at Demo Day reporting $1.7 million in contracts from DARPA and a Fortune 500 cosmetics company, and attracts backing from Khosla Ventures.
- Operations ended
The company quietly winds down between 2017 and 2018; in 2018 founder Srivastava starts a new company, Synthetic Minds, and the 20n/act platform is later open-sourced.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Software predicted biosynthetic routes in engineered microbes
- 02
First biological route to acetaminophen engineered
- 03
$1.7M in DARPA and Fortune 500 contracts at YC Demo Day
- 04
Design-only model lost to full-stack rivals; wound down 2017-2018